US drug chief: More 'breakthrough' designations soon to come
This article was originally published in Scrip
Executive Summary
Drug makers wasted no time in taking advantage of a new program aimed at expediting the development and review processes for medicines intended to treat serious or life-threatening diseases – with the US FDA's new breakthrough therapies designation already fast becoming popular.